Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Hiroshi, Terasaki"'
Autor:
Kana Watanabe, Ryota Saito, Eisaku Miyauchi, Hiromi Nagashima, Atsushi Nakamura, Shunichi Sugawara, Nobuyuki Tanaka, Hiroshi Terasaki, Tatsuro Fukuhara, Makoto Maemondo
Publikováno v:
Cancers, Vol 15, Iss 17, p 4231 (2023)
Background: Osimertinib was first approved for the treatment of non-small cell lung cancer (NSCLC) in patients who have developed the epidermal growth factor receptor (EGFR) T790M mutation after treatment with EGFR tyrosine kinase inhibitors (TKIs).
Externí odkaz:
https://doaj.org/article/51224864e06f4072be6e5ed8c791e226
Autor:
Yuki Kojima, Emi Noguchi, Tomomi Yoshino, Shigehiro Yagishita, Shu Yazaki, Hitomi S. Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Tatsunori Shimoi, Ayaka Kazama, Hiroshi Terasaki, Sachiro Asano, Yasuhiro Fujiwara, Akinobu Hamada, Kenji Tamura, Kan Yonemori
Publikováno v:
Diagnostics, Vol 13, Iss 12, p 2040 (2023)
Although circulating tumour DNA (ctDNA)-based next-generation sequencing (NGS) is a less invasive method for assessing ESR1 mutations that are essential mechanisms of endocrine therapy resistance in patients with oestrogen receptor-positive breast ca
Externí odkaz:
https://doaj.org/article/5c672b95ed7649a29f346277c875dfae
Autor:
Yonemori, Yuki Kojima, Emi Noguchi, Tomomi Yoshino, Shigehiro Yagishita, Shu Yazaki, Hitomi S. Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Tatsunori Shimoi, Ayaka Kazama, Hiroshi Terasaki, Sachiro Asano, Yasuhiro Fujiwara, Akinobu Hamada, Kenji Tamura, Kan
Publikováno v:
Diagnostics; Volume 13; Issue 12; Pages: 2040
Although circulating tumour DNA (ctDNA)-based next-generation sequencing (NGS) is a less invasive method for assessing ESR1 mutations that are essential mechanisms of endocrine therapy resistance in patients with oestrogen receptor-positive breast ca
Autor:
Hiroshi Terasaki, Tatsuya Kusumi
Publikováno v:
NTT Technical Review. 20:29-33
Autor:
Shohei NOGAMI, Susumu YOSHIOKA, Yuki HOSOKAWA, Miki MOCHIZUKI, Hirotake WAKAMATSU, Hiroshi TERASAKI, Mitsunobu SHIMADU
Publikováno v:
BUNSEKI KAGAKU. 71:59-68
Publikováno v:
JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY. 38:191-198
Autor:
Yuki Kojima, Emi Noguchi, Tomomi Yoshino, Shigehiro Yagishita, Shu Yazaki, Hitomi S Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Tatsunori Shimoi, Ayaka Kazama, Hiroshi Terasaki, Sachiro Asano, Yasuhiro Fujiwara, Akinobu Hamada, Kenji Tamura, Kan Yonemori
Background: ESR1 gene mutations are an essential mechanism of resistance to endocrine therapy in patients with oestrogen receptor-positive breast cancer. ESR1 mutations can exist at multiple sites and are typically detected polyclonally after endocri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecb0d4c0037454e036b5cc3c222d2c07
https://doi.org/10.21203/rs.3.rs-1410750/v1
https://doi.org/10.21203/rs.3.rs-1410750/v1
Autor:
Kana Watanabe, Tatsuro Fukuhara, Yoko Tsukita, Mami Morita, Aya Suzuki, Nobuyuki Tanaka, Hiroshi Terasaki, Toshihiro Nukiwa, Makoto Maemondo
Publikováno v:
Canadian Respiratory Journal, Vol 2016 (2016)
Introduction. Rebiopsies have become more crucial in non-small cell lung cancer (NSCLC). Instead of invasive biopsies, development of collecting biological data of the tumor from blood samples is expected. We conducted a prospective study to assess t
Externí odkaz:
https://doaj.org/article/390d6b5ef19e4164931fe7c72706c288
Publikováno v:
Bunseki kagaku. 66:445-451
Autor:
Hiroshi Terasaki, Akinobu Hamada, Tomomi Yoshino, Shigehiro Yagishita, Kan Yonemori, Kenji Tamura, Emi Noguchi, Sachiro Asano, Yuki Kojima
Publikováno v:
Cancer Research. 80:1975-1975
Background: The occurrence of ESR1 mutations is rare in estrogen receptor (ER) positive primary breast cancer patients; however these mutations are frequently reported in ER positive recurrent breast cancer patients pretreated with endocrine therapy.